ReviewCell communication and signaling : CCS2026
NOTCH3 Mutations in CADASIL: a multicellular perspective on neurodegeneration.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MRI markers of brain fluid dynamics link reduced blood-brain barrier water exchange rate to disease severity in CADASIL.European stroke journal · 2026Article
- Transcriptomic Evidence of MAS1 Receptor Dysregulation and a Failed Compensatory State in Human Vascular Cognitive Impairment.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary cerebral small-vessel disease caused by NOTCH3 cysteine-altering mutations. Clinical evidence, including early-onset migraines, psychiatric symptoms, and diffuse white-matter hyperintensities preceding strokes, suggests a nonvascular pathology. NOTCH3 is broadly expressed in neural progenitors, neurons, astrocytes, oligodendrocytes, and brain microvascular endothelial cells (BMECs), and is responsible for neurodevelopment, blood-brain barrier (BBB) homeostasis, glymphatic function, and myelination. In vitro studies suggest that mutant NOTCH3 disrupts hippocampal neurogenesis via impaired neural stem cell self-renewal, causes astrocytic aquaporin-4 (AQP4) mislocalisation leading to glymphatic failure, compromises endothelial integrity, and derails oligodendrocyte maturation. These dysfunctions can collectively perturb neurovascular unit (NVU) integrity, accelerating neurodegeneration independent of infarcts. This review puts together evidence for nonvascular NOTCH3 pathology, emphasizing its role in neuroglial development and NVU crosstalk. We aim to reframe CADASIL as a multicellular interface disorder that stems from neurodevelopmental pathways, suggesting that advanced 3D in vitro NVU models to unravel disease mechanisms leading to the new therapeutic strategies that target glial and neuronal NOTCH3 signalling to mitigate early symptoms and slow progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.